Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366982 | 0.87 | TTR (0.48) | TTRALBMEN1KMT2ACA9 | |
| SCHEMBL11862401 | 0.84 | TTR (0.75) | TTRALBMEN1KMT2ACA9 | |
| SCHEMBL31053022 | 0.84 | TTR (0.45) | TTRALBMEN1KMT2ACA9 | |
| SCHEMBL11871037 | 0.84 | TTR (0.75) | TTRALBMEN1KMT2ACA9 | |
| SCHEMBL11835656 | 0.79 | ERN1 (0.41) | TTRALBMEN1KMT2AVCAM1 | |
| SCHEMBL4959352 | 0.79 | XDH (0.41) | TTRALBMEN1KMT2AGPR35 | |
| SCHEMBL9244309 | 0.79 | TTR (0.45) | TTRALBMEN1KMT2ACA9 | |
| SCHEMBL11332961 | 0.77 | TTR (0.43) | TTRALBMEN1KMT2ACA9 | |
| SCHEMBL28490634 | 0.76 | VCAM1 (0.58) | TTRMEN1KMT2AVCAM1GPR35 | |
| SCHEMBL29216775 | 0.76 | SELL (0.43) | TTRALBMEN1KMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2023-08-17 | — | — | US | disclosed |
| EP-3986420-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | Mitopower LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020257283-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC | 2020-12-24 | — | — | US | disclosed |
| EP-1098641-B1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | ST JUDE PHARMACEUTICALS INC (US) | 2016-04-27 | — | — | EP | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-20150056160-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20100056643-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | ST. JUDE PHARMACEUTICALS, INC. | 2010-03-04 | — | — | US | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1098641-A4 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | ST JUDE PHARMACEUTICALS INC (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1098641-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | Texas Pharmaceuticals, Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000006143-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| US-5629406-A | AMINO ACID DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0587311-A1 | Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TTR 3990/4885ALB 3748/4885MEN1 3295/4885 |
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | TTR 3440/4885ALB 4475/4885MEN1 3810/4885 |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | TTR 3440/4885ALB 4475/4885MEN1 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.